Human endoxifen plasma exposure: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

Endoxifen AUC fell 12.4% with curcumin plus piperine, p=0.02.
Curcumin plus piperine regimen → Human endoxifen plasma exposure source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/curcumin-research/30909366.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527", "start_char": 0, "end_char": 1407, "text_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527"}
experimental_model
Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients
exposure
Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day
limitations
Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established.
nutrient_topic
Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
organism
Homo sapiens
plain_language
The combination reduced exposure to tamoxifen's active metabolite.
primary_references
[curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403
tissue_or_cell_type
Plasma drug and metabolite AUC
Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 970–981
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients · source_derived_draft · unverified_draft
### curcumin-endoxifen-combination Endoxifen AUC fell 12.4% with curcumin plus piperine, p=0.02. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The combination reduced exposure to tamoxifen's active metabolite. organism: Homo sapiens tissue_or_cell_type: Plasma drug and metabolite AUC experimental_model: Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients limitations: Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established. exposure: Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day evidence_span: {"source_cache": "artifacts/curcumin-research/30909366.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527", "start_char": 0, "end_char": 1407, "text_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527"} [curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403
Complete structured claim and evidence
Endoxifen AUC was 7.7% lower with curcumin alone; the confidence interval crossed zero and p=0.07.
Curcumin → Human endoxifen plasma exposure source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/curcumin-research/30909366.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527", "start_char": 0, "end_char": 1407, "text_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527"}
experimental_model
Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients
exposure
Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day
limitations
Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established.
nutrient_topic
Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
organism
Homo sapiens
plain_language
The curcumin-only result suggested a decrease but was not conventionally significant.
primary_references
[curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403
tissue_or_cell_type
Plasma drug and metabolite AUC
Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 957–968
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients · source_derived_draft · unverified_draft
### curcumin-endoxifen-curcumin Endoxifen AUC was 7.7% lower with curcumin alone; the confidence interval crossed zero and p=0.07. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The curcumin-only result suggested a decrease but was not conventionally significant. organism: Homo sapiens tissue_or_cell_type: Plasma drug and metabolite AUC experimental_model: Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients limitations: Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established. exposure: Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day evidence_span: {"source_cache": "artifacts/curcumin-research/30909366.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527", "start_char": 0, "end_char": 1407, "text_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527"} [curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Human endoxifen plasma exposure